GSK announced agreements with 10 plaintiff firms representing ~80,000 claimants (93% of pending US state-court Zantac cases) to pay up to $2.2 billion in aggregate, with full implementation expected by end of H1 2025; GSK admitted no liability.

Related news

1. Jul 25, 2026

   Zantac / Ranitidine (NDMA Cancer)

   Public Search Interest in Zantac and NDMA Terms Rises Sharply

   Google Trends data recorded a sharp week-over-week rise in searches for 'ranitidine' (+300%), 'zantac lawsuit attorneys' (+150%), and 'ndma' (+170%), along with breakout search activity for 'zantac lawsuit update 2022,' 'cetirizine recall,' and 'recall on zantac.'

   Source: trends.google.com

2. Jul 24, 2026

   Zantac / Ranitidine (NDMA Cancer)

   Public Search Interest in Zantac Lawsuit Topics Spikes

   Google Trends data detected sharp increases in searches for terms including 'ranitidine' (up 300%), 'zantac lawsuit attorneys' (up 150%), and 'ndma' (up 170%), along with breakout search activity for 'zantac lawsuit update 2022' and 'recall on zantac,' according to Google Trends.

   Source: trends.google.com

3. Jul 20, 2026

   Zantac / Ranitidine (NDMA Cancer)

   MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) omnibus Daubert order (Doc 6120, 341 pages): ALL defendants' Daubert motions on general causation GRANTED and defendants' summary judgment motion GRANTED — plaintiffs 'fail to produce admissible primary evidence of general causation' that ranitidine causes cancer, ending the federal MDL claims.

   MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) omnibus Daubert order (Doc 6120, 341 pages): ALL defendants' Daubert motions on general causation GRANTED and defendants' summary judgment motion GRANTED — plaintiffs 'fail to produce admissible primary evidence of general causation' that ranitidine causes cancer, ending the federal MDL claims. Verified from the court order itself.

   Source: gsk.com